April 22, 2018 – By Eugene Smith. Apr 22 is a negative day so far for iShares Nasdaq Biotechnology ETF (NASDAQ:IBB) as the ETF is active during the day after losing 0.88% to hit $104.96 per share. The exchange traded fund has 9.03B net assets and 2.58% volatility this month. Over the course of the …
The Hospitals Biotechnology Market report explores and analyses the essential factors of market depending on present industry situations, market needs, business strategies and the growth condition.This report isolates the Hospitals Biotechnology market capacity, production, market share, price, …
submitted by /u/iridescent_omkar [link] [comments]
Two-hundred biotech allies from more than 40 different states visited Washington D.C. this week. These advocates met with policymakers on Capitol Hill and in the administration to share BIO’s vision and policy priorities for a strong biotech industry. When it came to the topic of prescription drug costs, part of our message to both Republican …
Read Article: The Latest Good News on Prescription Drug Costs
The House Agriculture Committee approved on Wednesday, April 18, amendments to the panel’s Farm Bill addressing some key BIO policy priorities: Trade: An amendment by Rep. Neal Dunn (R-Fla.) would create a Biotechnology and Agricultural Trade Program. This amendment is reflective of BIO-supported R. 5379, the Growing American Food Exports Act, introduced by Reps. Dunn …
Read Article: BIO Applauds Farm Bill Amendments Addressing Ag Biotech
As BIO CEO, everywhere I go – including Tokyo and Hong Kong last month – I talk about what sets America apart as the country responsible for innovating more new medicines than the rest of the world combined. Other countries have great scientists, but no other country can match U.S. innovation policy, our world-leading biotech …
Read Article: Orrin Hatch Is an Historic Figure in Biotechnology
Disclaimers: GuruFocus.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended …
At the end of March, the U.S. Department of Agriculture, the government agency regulating genetically engineered plants, clarified that under its biotechnology regulations the agency “does not regulate or have any plans to regulate plants that could otherwise have been developed through traditional breeding techniques.” Essentially, this statement signals that the USDA does not, and …
Read Article: Gene Editing Is A Continuum of Plant Breeding
Last year Jerry Feitelson was accepted into BIO’s Start-up Stadium at the annual BIO International Convention. Armed with his six-minute pitch, the CEO and Co-founder of Agribody Technologies, Inc. (ATI) stood before the assembled judges and explained how his technology might one day help to save the planet. ATI was one of a select group …
Read Article: Anything Could Happen at #BIO2018 Start-up Stadium
In the world of biotechnology investment, notorious for share price volatility and it “high-risk return” nature, investing in exchange traded funds (ETFs) or mutual funds might be the sensible route for retail investors. The minefield of sometimes-undecipherable medical and technical terms and acronyms, …